Capricor Therapeutics and CureDuchenne to Host Webinar on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET

LOS ANGELES, June 15, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq: CAPR ), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne , a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar on Friday, June 19, 2015 at 3:00 p.m. ET/noon PT.

Speakers include:

  • Dr. Linda Marbán, Chief Executive Officer of Capricor Therapeutics
  • Dr. Andrew Hamer, Vice President of Medical Affairs of Capricor
  • Debra Miller, Founder and Chief Executive Officer of CureDuchenne
  • Dr. Michael Kelly, Chief Scientific Advisor for CureDuchenne

Capricor's upcoming HOPE-DUCHENNE clinical trial will be discussed. The HOPE-DUCHENNE trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. CureDuchenne Ventures has invested in Capricor to support the development of its clinical program for Duchenne.

The U.S. Food and Drug Administration (FDA) has cleared Capricor's Investigational New Drug Application (IND) for the clinical development of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy (DMD) related cardiomyopathy. Heart failure is the leading cause of death in patients with Duchenne.

To join the webinar please call (844) 337-8088 and enter conference ID number 64152106. Visit here: ( https://cc.readytalk.com/cc/s/registrations/n...5me0up4wnx ) to register online.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (Nasdaq: CAPR ) is a clinical-stage biotechnology company with expertise in the field of cardiovascular disease aiming to develop novel therapies for diseases with significant unmet medical needs. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: Cenderitide, a natriuretic peptide receptor agonist, and CAP-1002, a cardiac cell therapy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com .

About CureDuchenne Ventures and CureDuchenne

CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has a successful track record of supporting research and raising awareness of the disease.

CureDuchenne is a national nonprofit organization located in Newport Beach, California, dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide. CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne. With the help of CureDuchenne's distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have advanced into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; scope, duration, validity and enforceability of intellectual property rights; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact our business are set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 16, 2015, in our Registration Statement on Form S-1, as filed with the Securities and Exchange Commission on March 6, 2015 and in our Quarterly Report on Form 10-Q for the period ending March 31, 2015, as filed with the Securities and Exchange Commission on May 13, 2015. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we assume no obligation to update these forward-looking statements.

For more information, please contact: Capricor Therapeutics, Inc. AJ Bergmann, Vice President of Finance +1-310-358-3200 Media Relations Russo Partners Christopher Hippolyte +1-646-942-5634 Investor Relations: Russo Partners Robert Flamm, Ph.D. +1-212-845-4226

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 45

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Monotype Unveils Font Tool for Adobe: A Game-Changer?

Updated Category News Views 106

Monotype Connect: Fonts Meet Convenience Imagine fighting through a blizzard with a flashlight. That's how designers juggle fonts without a central tool. Well, Monotype's got them covered with the new Connect panel for Adobe apps—a beacon of efficiency spotted at Adobe MAX 2026 in Miami Beach. Efficiency and Brand Unity: Partners in Design Now, here’s why this isn’t...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 52

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Panasonic Showcases Rugged Tech at NATO Edge 26

Updated Category News Views 56

Panasonic Heads to Turkey with Tactical Tech Panasonic's got its sights set on proving a point at NATO Edge 26, busting out its TOUGHBOOK line and showing just how these rugged laptops aren't just tough, but also strategically essential. From November 17th through 19th, down in Turkey, these devices are taking the spotlight as they embrace the operational challenges of...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 111

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 77

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 45

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 83

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Blain’s Farm & Fleet Shines in Newsweek’s Best Online Shops

Updated Category News Views 97

Blain’s Farm & Fleet Achieves Recognition for Online Excellence Blain's Farm & Fleet, a well-respected name in retail, has been honored as one of Newsweek’s Best Online Shops for 2025. This recognition marks the fourth consecutive year the company has earned this prestigious title, reflecting its unwavering commitment to quality and service across its online platform....

Continue Reading
Statkraft AS Secures NOK 3 Billion Through Commercial Paper

Updated Category News Views 127

Statkraft AS Secures Significant Funding Statkraft AS has successfully issued a commercial paper totaling NOK 3.0 billion, showcasing the company's strategic approach to financing. This financial instrument offers a coupon rate of 3M NIBOR plus 0.205%, reflecting favorable conditions in financial markets. Details of the Commercial Paper The commercial paper is designed...

Continue Reading
Soleno Therapeutics Launches $100 Million Stock Buyback Program

Updated Category News Views 143

Soleno Therapeutics Initiates Major Buyback Program Soleno Therapeutics Inc. (NASDAQ: SLNO) has announced a significant development in its corporate strategy by launching a $100 million share repurchase program. This move comes as the company seeks to enhance shareholder value amidst an environment where its stock has been deemed undervalued by market analysts. Details of...

Continue Reading
Brentwood Associates Launches $410 Million Fund for Watermill

Updated Category News Views 383

Overview of the New Continuation Fund Brentwood Associates, a leading private equity firm known for its strategic and growth-oriented investments, has officially closed an impressive $410 million continuation fund aimed at fueling the expansion of Watermill Express, LLC. This fund's purpose is to enhance the operational capabilities of Watermill Express, a prominent...

Continue Reading
Great Lakes Dredge & Dock Corporation Upgraded to B- Rating

Updated Category News Views 105

Great Lakes Dredge & Dock Corporation Receives S&P Upgrade Great Lakes Dredge & Dock Corporation ("Great Lakes" or the “Company”) (NASDAQ: GLDD), the leading provider of dredging services in the United States, has announced a notable upgrade to its issuer credit rating by S&P Global Ratings. The rating has been elevated from “CCC+” to “B-,” signaling a...

Continue Reading